Protagonist Therapeutics Inc
NASDAQ:PTGX

Watchlist Manager
Protagonist Therapeutics Inc Logo
Protagonist Therapeutics Inc
NASDAQ:PTGX
Watchlist
Price: 87.34 USD 0.09% Market Closed
Market Cap: 5.5B USD

Relative Value

The Relative Value of one PTGX stock under the Base Case scenario is 28.13 USD. Compared to the current market price of 87.34 USD, Protagonist Therapeutics Inc is Overvalued by 68%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PTGX Relative Value
Base Case
28.13 USD
Overvaluation 68%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
36
vs Industry
51
Median 3Y
13.4
Median 5Y
17.5
Industry
8
Forward
80.5
vs History
0
vs Industry
10
Median 3Y
9.2
Median 5Y
-4.2
Industry
23.5
Forward
-44.6
vs History
3
vs Industry
10
Median 3Y
8.3
Median 5Y
-7.3
Industry
21.9
vs History
3
vs Industry
9
Median 3Y
8.3
Median 5Y
-7.3
Industry
24.3
vs History
0
vs Industry
20
Median 3Y
4.2
Median 5Y
4.2
Industry
3.2
vs History
26
vs Industry
45
Median 3Y
10.6
Median 5Y
13.3
Industry
8.1
Forward
72
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.1
vs History
0
vs Industry
11
Median 3Y
7.9
Median 5Y
-2.3
Industry
5.9
Forward
-33
vs History
0
vs Industry
10
Median 3Y
7.9
Median 5Y
-2.3
Industry
6.2
Forward
-32.1
vs History
1
vs Industry
11
Median 3Y
6.5
Median 5Y
-4.9
Industry
7.7
vs History
1
vs Industry
8
Median 3Y
6.5
Median 5Y
-4.9
Industry
6.3
vs History
41
vs Industry
22
Median 3Y
36.1
Median 5Y
36.1
Industry
5.6

Multiples Across Competitors

PTGX Competitors Multiples
Protagonist Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Protagonist Therapeutics Inc
NASDAQ:PTGX
5.5B USD 26.1 118.8 238.6 256.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 845 618.3 -160 863.2 -195 339.2 -193 110.2
US
Abbvie Inc
NYSE:ABBV
405.4B USD 6.8 172.6 16.7 23.7
US
Amgen Inc
NASDAQ:AMGN
175.8B USD 4.9 25.1 18.1 18.1
US
Gilead Sciences Inc
NASDAQ:GILD
151.3B USD 5.2 18.7 12.5 12.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.8B USD 9.8 31.2 22.9 23.9
US
Epizyme Inc
F:EPE
94.1B EUR 2 081.5 -531.1 -578.4 -562.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.7B USD 5.7 17.9 17 19.3
AU
CSL Ltd
ASX:CSL
83.3B AUD 3.6 18.6 12.6 15.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
53B USD 16.5 1 216.4 164 198.9
NL
argenx SE
XBRU:ARGX
43.8B EUR 14.2 33.5 57.7 59.3
P/E Multiple
Earnings Growth PEG
US
Protagonist Therapeutics Inc
NASDAQ:PTGX
Average P/E: 183.6
118.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 863.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
172.6
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.1
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.7
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.2
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -531.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.9
10%
1.8
AU
CSL Ltd
ASX:CSL
18.6
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 216.4
N/A N/A
NL
argenx SE
XBRU:ARGX
33.5
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Protagonist Therapeutics Inc
NASDAQ:PTGX
Average EV/EBITDA: 62.2
238.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 339.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.7
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.1
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.9
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -578.4 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17
11%
1.5
AU
CSL Ltd
ASX:CSL
12.6
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
164
N/A N/A
NL
argenx SE
XBRU:ARGX
57.7
810%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Protagonist Therapeutics Inc
NASDAQ:PTGX
Average EV/EBIT: 69.8
256.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 110.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.7
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.1
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.9
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -562.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.3
13%
1.5
AU
CSL Ltd
ASX:CSL
15.7
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
198.9
N/A N/A
NL
argenx SE
XBRU:ARGX
59.3
N/A N/A